Mesoblast Raises $260 Million for Ryoncil® Launch and Expanded Development

Key Highlights

  • Capital Raised: A$260 million (US$160 million) raised through a global private placement at A$2.50 per share.
  • Shareholder Support: Placement primarily backed by major shareholders in the US, UK, and Australia.

Fund Allocation

  1. US Commercial Launch:
    • Rollout of Ryoncil® (remestemcel-L) for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD).
    • Ryoncil® is the first and only FDA-approved mesenchymal stromal cell (MSC) therapy for this condition.
  2. Clinical Development:
    • Acceleration of a Phase 3 study for chronic low back pain (CLBP), with active recruitment underway.
  3. Manufacturing Expansion:
    • Scale-up of commercial production to meet anticipated global demand.
  4. Working Capital:
    • Support for corporate operations and general business activities.

CEO Commentary

Dr. Silviu Itescu, Mesoblast’s Chief Executive, said:

“We appreciate the strong support from our shareholders as we scale up production and provide hospitals with Ryoncil®, the first FDA-approved mesenchymal stromal cell therapeutic, to treat children with life-threatening SR-aGvHD.”

About Mesoblast

Mesoblast is a global leader in allogeneic cellular medicines for inflammatory diseases. The company’s proprietary mesenchymal lineage cell therapy technology targets severe inflammation, reducing immune system damage.

Key Products:

  1. Ryoncil®:
    • Approved for pediatric SR-aGvHD.
    • Development underway for adult SR-aGvHD and biologic-resistant inflammatory bowel disease.
  2. Rexlemestrocel-L:
    • Focused on treating heart failure and CLBP.

Global Reach:

  • Commercial partnerships in Japan, Europe, and China.
  • Manufacturing processes ensure industrial-scale, cryopreserved, off-the-shelf cellular medicines for global availability.

Intellectual Property:

  • Over 1,000 patents and applications across major markets, with protections extending through 2041.

Investor Takeaways

The capital injection positions Mesoblast to execute a transformative year, focusing on the commercial success of Ryoncil® and the advancement of its clinical pipeline. The company’s unique, patent-protected technology and FDA approval establish it as a leader in the growing cell therapy market.

Key Dates:

  • Keep an eye on progress in Ryoncil® uptake and updates on the CLBP Phase 3 study.